<DOC>
	<DOCNO>NCT01058642</DOCNO>
	<brief_summary>The primary purpose study evaluate analgesic efficacy ADL5747 participant postherpetic neuralgia ( PHN ) . The secondary objective study evaluate safety , tolerability , pharmacokinetics ADL5747 .</brief_summary>
	<brief_title>Study Assess Efficacy , Safety , Tolerability ADL5747 Participants With Postherpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Key inclusion Criteria : diagnosis PHN ( define pain present least 3 month heal herpes zoster rash ; upper limit duration PHN ) average daily pain score least 4 numeric pain rating scale ( 010 ) start baseline week Treatment Period 1 ( Day 7 ) start first week Treatment Period 1 ( Day 1 ) willing able understand comply protocol requirement , dietary dosing regimen , protocol instruction restriction ( example , forgo use normal pain medication protocol specify prohibited medication duration study ) male participant , surgically sterile agree use appropriate method contraception sexual partner surgically sterile use insertable , injectable , transdermal , combination oral contraceptive approve deem highly effective United States Food Drug Administration ( FDA ) first dose study medication 30 day last dose study medication Day 49 female participant childbearing potential , use insertable , injectable , transdermal , combination oral contraceptive approve deem highly effective FDA first dose study medication 30 day last dose study medication Day 49 negative result serum pregnancy test start screen period obtain informed consent determine eligibility study ( Day 37 14 ) urine pregnancy test start first week Treatment Period 1 ( Day 1 ) ( woman surgically sterile [ example , hysterectomy , tubal ligation ] postmenopausal [ ≥ 55 year old , menses least 2 year ; &lt; 55 year old , follicle stimulate hormone concentration within postmenopausal range &gt; 40 milliInternational Units per milliliter ( mIU/mL ) 17 β estradiol level &lt; 37 picograms per milliliter ( pg/mL ) ] also eligible participate ) Key pregnant lactating significant skin lesion could interfere pain assessment history seizure history abnormal electroencephalographic result time ( participant history febrile seizures age 6 year may enrol ) previous neurolytic neurosurgical therapy PHN treatment include local anesthetic nerve block within 30 day start baseline week Treatment Period 1 ( Day 7 ) type pain may impair selfassessment pain due PHN , determine investigator sponsor 's medical monitor , history clinical manifestation significant renal , hepatic , hematologic , cardiovascular , metabolic , gastrointestinal , neurologic , psychiatric , condition would preclude participation study active malignancy type ( participant history successfully treat malignancy &gt; 5 year schedule first dose study medication participant treat basal squamous cell cancer may enrol ) medical history condition may interfere drug absorption ( example , stomach resection ) currently use protocol specify prohibited medication absence appropriate washout currently take moderate strong inhibitor inducer cytochrome P4503A ( CYP3A ) inhibitor P glycoprotein transporter estimate glomerular filtration rate ( GFR ) less equal 60 mL/min calculate Cockcroft Gault equation alanine aminotransferase and/or aspartate aminotransferase level least 2 time upper limit normal history substance abuse dependence within previous 5 year , include alcohol positive result urine drug screen start screen period , start baseline week , start first week Treatment Period 1 ( Day 37 Day 1 ) ; participant may enrol positive result due medication ( ) prescribe participant permit protocol history suicide attempt judge clinically serious risk suicide score 29 Beck Depression InventoryII start screen period ( Day 37 Day 14 ) history allergy acetaminophen ( rescue medication study ) history intolerance pregabalin document failure respond maximally tolerate dose pregabalin ever receive investigational drug ADL5747 participate clinical study involve investigational product receive product within 30 day schedule administration study medication study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>pain</keyword>
	<keyword>delta opioid receptor agonist</keyword>
</DOC>